imo we'll know the future perhaps when they share ORR from 20+ 700mg patients. ORR on 20 of them takes us into the summer: june or july. 30% PRs / 60% DCR is what i consider the line that needs to be crossed. need a buffer for the sample size. if that is achieved at 700mg in a liver mets / KRAS inclusive cohort, then we are on the verge of something great, but still have a challenge. Also need mPFS of 6+ months, which might be challenging. If leronlimab at 700mg hits those 3 marks, particularly with all 30 at 700mg recorded, then its got everything covered and is a must-have asset for BP.
6